{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053824","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2026-08-06T11:04:40+00:00","discovered_at":"2026-08-06T11:10:07.335831+00:00","generated_at":"2026-08-06T11:10:12.402932+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Opus Genetics Q2 net loss $8.1M; LCA5 trial enrollment completed","bullets":["Net loss of $8.1M ($0.08 basic EPS) vs $7.4M loss in Q2 2025; revenue fell to $0.8M from $2.9M.","Cash and equivalents $88.8M; runway into 2029, excluding potential warrant proceeds or milestones.","OPGx-BEST1 Cohort 1 topline data expected second week of September 2026.","OPGx-LCA5 registrational trial enrollment completed; dosing expected Q4 2026 with topline data by end of 2027.","OPGx-RDH12 enters clinic Q4 2026; OPGx-MERTK clinical testing Q1 2027; OPGx-RHO clinical testing H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053824","json":"https://secwatch.observer/filing/0001628280-26-053824.json","markdown":"https://secwatch.observer/filing/0001628280-26-053824.md","text":"https://secwatch.observer/filing/0001628280-26-053824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/0001628280-26-053824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/ird-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:10:12.402932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}